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Background: Essential tremor (ET) and Parkinson’s disease (PD) are considered distinct disorders. The aim of the
study was to look for a link or any distinguishing features by transcranial sonography (TCS), together with the
clinical examination findings in a group of patients with overlapping phenotype of ET and PD (ET-PD).
Methods: A prospective observational case-control study was carried out from the 3rd January 2011 until 30th January
2013 at the Hospital of Lithuanian University of Health Sciences. The final study group consisted of 15 patients with
ET-PD, 116 patients with ET-only and 141 patients with PD-only. The control group included 101 subjects. Clinical
diagnosis was of a diagnostic standard.
Results: The main ultrasonographic findings in the ET-PD group were similar to those of the PD-only: hyperechogenicity
of the substantia nigra (66.7%, p < 0.001) and nuclei raphe interruptions/absence (38.5%, p < 0.001). The single
distinguishing TCS finding in ET-PD group was a lentiform nucleus hyperechogenicity (26.7%), however this was
only significant when compared to controls (p = 0.006). An asymmetrical onset of symptoms (73.3%) in ET-PD group
was characteristic to PD-only. The ET-PD patients had the longest disease duration (median 6 years, p < 0.001), the most
frequent rate of positive family history (53.3%, p = 0.005), rather low prevalence of cogwheel rigidity (26.7%, p < 0.001),
and higher mean Hoehn & Yahr scores compared to PD-only (2.6 ± 0.8 vs. 1.8 ± 0.8, p = 0.012).
Conclusions: The main TCS findings of the present study in patients with overlapping ET-PD phenotype were similar
to the PD-only group. The highest positive family history rate among ET-PD patients indicates a strong hereditary
predisposition and needs genetic underpinnings. Some ET patients, who look like they may be developing co-morbid
PD clinically, may have an alternative diagnosis for Parkinsonism, which could be delineated by TCS examination.
Keywords: Essential tremor, Parkinson’s disease, Hyperechogenicity of the substantia nigra, Phenotype,
Transcranial sonographyBackground
Essential tremor (ET) is one of the most common move-
ment disorders, followed by Parkinson’s disease (PD) [1,2].
ET affects up to 14% and PD up to 1% of the population
aged 65 years and over [3,4]. ET and PD are considered
distinct disorders. However, an overlap of some clinical
features in individual patients may appear [5]. Since the
diagnosis of both ET and PD remains based only on the* Correspondence: kristina.lauckaite@lsmuni.lt
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reproduction in any medium, provided the orclinical criteria, many questions regarding a nosological
association remain unanswered [4-11]. Misdiagnosis be-
tween the two is still common due to a lack of objective
differential measurement [12].
Another debated controversy is whether ET should be
viewed as a mono-symptomatic (“benign”) disorder, or
whether it is a syndrome of several diseases including
neurodegenerative [6,13,14]. PD can be sometimes viewed
as “benign” in some tremor-dominant (TD) patients, as it
progresses very slowly [9].
Some attempts were made to find specific biomarkers,
which could help to differentiate or to link ET-PD patientsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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issue, published until 2011, were summarized in a thorough
review of Fekete and Jankovic [15]. A few studies were
published later, which add valuable information, and
questions. Patients with ET–PD obtained significantly
lower scores compared to ET-only on several cognitive
tests, and showed more frequent familial history, and
lower levodopa responsiveness [16]. ET patients who
develop PD may have distinct pre-PD motor features
than their counterparts with ET who do not develop
co-existing PD [17]. Although the results of a follow-up
radionuclide imaging study with 123I-Ioflupane (DaTscan)
in ET patients did not support the hypothesis of a link
between ET and PD, but in ET patients striatal binding
was significantly reduced compared to healthy controls
[18]. The most recent post-mortem study of 89 ET patients
reported that 11 (12.4%) had pathological findings of
progressive supranuclear palsy (PSP) [19]. This raised
other questions, whether ET patients are at an increased
risk of developing PSP, and what proportion of ET patients
who develop presumed PD or Alzheimer’s disease, actually
have PSP [19].
A hyperechogenicity of the substantia nigra (SN+)
without any abnormalities in other brain structures is a
common finding in transcranial ultrasound (TCS) of PD
patients [20]. Recently, imaging by TCS has been recom-
mended (European guidelines): 1) for the differential diag-
nosis of PD from atypical or secondary parkinsonian
syndromes (PS); 2) for early PD diagnosis, and 3) for the
detection of subjects at risk for PD [21]. However, TCS
shows the SN + in a percentage of non-PD patients. This
echo feature is found in up to 26% of ET patients, compared
to approximately 10% of healthy controls [20,22,23].
The aim of the study was to look for a link or any dis-
tinguishing features by TCS. And to further elucidate
the relationship between ET and PD, clinical examination
findings in a group of patients who had already presented




A prospective observational case-control study was per-
formed during a period from the 3rd of January 2011, until
the 30th of January 2013, at the Hospital of Lithuanian
University of Health Sciences (HLUHS, Kaunas, Lithuania).
Initially, 433 subjects (332 patients and 101 controls) were
referred for examinations from both Out-patient and
In-patient units of the Neurology Department. Control
subjects were recruited from the patients who were referred
for carotid ultrasound and who had other neurological
diseases, but not including movement disorders.
After one year all medical records of the patients were
reviewed to see if the treating neurologists made anychanges to the final clinical diagnoses. Only the ET-PD
patients were invited for a re-consultation after a year, they
were all contacted by phone. After the study, if a patient of
any other group did not come for a re-consultation, the
diagnosis was classified as recorded at the time of the
last visit.
Of 332 patients directed for TCS, 46 patients (13.9%)
were excluded from the study because of bilateral tem-
poral acoustic bone insufficiency. In addition, 14 (4.9%)
patients were excluded because their diagnoses changed
or remained uncertain (N/A) after a follow-up: for 11
(2.5%) diagnosis remained N/A, for 1 (0.2%) diagnosis
converted to atypical PS, and for 2 (0.5%) patients diag-
nosis changed to secondary PS.
Thus, 373 subjects were eligible for the final analysis:
272 patients and 101 controls. The patient group con-
sisted of ET-PD (n = 15), PD-only (n = 141), and ET-only
(n = 116). The higher percentage of all patients (68.3%)
was referred for a de novo diagnosis. The majority of PD-
only patients were at an early stage of the disease (80.1%).
TD PD-only accounted for 48 (34%), non-TD–for 90
(63.8%), while 3 cases (2.1%) were N/A. When describing
PD subtypes in more details: 48 (34%) patients were TD
PD-only, 34 (24.1%)–postural instability gait disorder pre-
dominant (PIGD), 56 (39.7%)–mixed type, and the rest
3 (2.1%) already mentioned cases were N/A.
To serve the main purpose of the study, two important
requirements were: 1) a full clinical characterization of the
subset of patients with ET-PD phenotype; 2) an evaluation
of TCS findings in order to determine the impact of
this non-invasive, inexpensive, objective imaging tool
in diagnostic and therapeutic decisions, when the latter
phenotype is met in clinical practice.
Ethics
Before the study was initiated, permission was obtained
from Kaunas Regional Research Ethics Committee (No
BE-2-70). All subjects recruited gave a written informed
consent. Additionally, a written agreement from the
patients was obtained to reproduce the images and video
material anonymously.
Clinical approach
During a visit of every subject, a neurological examination
and a structured interview were performed (DŠ, BV, GD).
The case history data included: duration of symptoms,
topography, (a) symmetry, relation to voluntary move-
ments, posture and task, heredity. The subjects were
also asked about possible contact with toxic agents and
history of head traumas. The most effective pharmaco-
therapy was recorded.
The diagnostic standard in our study was a clinical diag-
nosis, made by a treating neurologist. Inclusion criteria
were: ≥18 years of age, a clinical diagnosis of idiopathic
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criteria: for probable PD–the United Kingdom Brain Bank
criteria [24], for definite or classic ET–the consensus
statement of the Movement Disorder Society [25], a
clinical diagnosis with overlapping features of ET-PD
(the Parkinsonian signs, such as bradykinesia, rest tremor,
newly considered in previously diagnosed and well-
documented ET-only patients), and TCS. Exclusion criteria
were a bilateral temporal acoustic bone window insuffi-
ciency in the TCS examination or diagnosis of atypical,
heredo-degenerative (cerebellar included), secondary PS,
dystonia and unclear diagnosis, which didn’t meet the
criteria for either ET or PD.
When clinically the diagnosis was debated, for those
patients DaTscan (General Electric Healthcare, the United
Kingdom) imaging was performed at the HLUHS, the
Department of Nuclear Medicine. For the atypical cases,
brain computed tomography (CT) and/or magnetic reson-
ance imaging (MRI, Siemens Magnetom Avanto Syngo,
1.5 T) scans were made (RG).
For a thorough assessment, both objective and subjective
questionnaires were applied. The clinician-rated scales that
we used included the Unified Parkinson’s Disease Rating
Scale (UPDRS), modified Hoehn and Yahr (H&Y) Stages
Scale, and the Hospital Anxiety and Depression (HAD)
Scale, the 36-item Short Form Survey (SF-36) that were
self-rated [26-28].
Ultrasonographic approach
TCS imaging was performed by one neurosonographer
(KL). The sonographer was blinded to the clinical data, but
still could see the examined subjects. We used a 2–5 MHz
phased array transducer on a commercially available
ultrasound system, Voluson 730 Expert (General Electrics
Healthcare, Austria). With the subjects laid in a supine
position, the transducer was placed over the pre-auricular
temporal acoustic window bilaterally. The ultrasound
beam was focused at a depth of 16.8/55Hz, manually
adapting gain and degree of compression to allow optimal
image quality at the mesencephalic, diencephalic and sella
media planes. The SN +we classified by a plot of an area
in cm2. The normative threshold values of the SN calcu-
lated in our laboratory were <0.20 cm2 (mean + 1 standard
deviation, SD) and <0.26 cm2 (mean + 2 SD) [29]. The
SN + was treated when it was enlarged at least on one
side. For the ventricular system, the normative values
were as follows: the third ventricle (V3) diameter <1.0 cm
(mean + 2 SD); the lateral ventricles (LV) <2.1 cm (mean +
1 SD) (for the generation of the normative threshold values,
see Additional file 1: Table S1).
Statistical analyses
An analysis was performed with a statistical package SPSS
version 19.0 (IBM, USA). Descriptive statistics were givenas absolute numbers, percentages, mean ± SD, median and
interquartile range (IQR). Normality of the variables was
explored by the Shapiro-Wilk test. For the comparisons of
non-parametric data, the Kruskal-Wallis test was used.
For parametric data, the means between three or four
groups were compared by analysis of variance (ANOVA),
and between two groups, the Student t test was used. For
categorical data χ2 criterion was used. Correlation analysis
of non-parametrical data was performed by Spearman’s
correlation, and of parametric, Pearson’s. A p value of




The sample of the ET-PD patients accounted for 5.5%
of all patients (15/272). The demographic and clinical
characteristics of each patient of the ET-PD group are
presented in Table 1. The mean age of ET-PD patients
was 69 ± 9.6 years (yrs), 60% were female, median
symptom duration was 6 yrs. In the ET-PD group, 11
of 15 (73.3%) patients had asymmetrical distribution of
tremor at onset. The disease for the majority of patients in
the PD-only group (n = 122, 86.5%) started asymmetric-
ally, whereas for the majority (n = 81, 73%) in ET-only, it
was bilateral (χ2 test, p < 0.001). Although, in the ET-only
group some patients still did not fit into the category of
classical ET-only, but exhibited the atypical features: 3
(2.6%) had cogwheel signs, 3 (2.6%) pyramidal signs, 2
(1.7%) postural instability and gait disorders, 2 (1.7%) sub-
tle bradykinesia; and 31 (26.7%) had asymmetrical onset of
tremor (χ2 = 233.5, p < 0.001). Out of 15 ET-PD patients, 8
(53.3%) had the onset of tremor after 50 yrs of age, and in
10 (66.7%) of them the ET-type tremor was present ≥5 yrs
before the onset of PD-related symptoms. For 11 (73.3%)
of ET-PD patients the mixed type (an action and/or pos-
ture plus of a rest) tremor-only was observed, and in 4
(26.7%)–the signs of bradykinesia/hypokinesia were de-
tected, combined to an action and/or posture tremor. The
topography of tremor in ET-PD patients on examination
was as follows: arm(s)–in 15 (100%), head–in 9 (60%), leg
(s)–in 3 (20%), voice–in 2 (13.3%). In PD-only patients
tremor involved arm(s) in 133 (94.3%), leg(s) in 78
(55.3%), and head in 11 (7.8%) of cases (χ2 test, p < 0.001).
A positive cogwheel sign was present in only 4 (26.7%) of
ET-PD patients.
More than a half (n = 8, 53.3%) of ET-PD patients de-
noted positive family history (FH) of tremor. Looking at
the primary data (before an exclusion of the patients due
to bilateral temporal acoustic bone insufficiency for
TCS) in the ET-PD group (n = 17): none (0/17) of the
patients from this group denoted positive family history
of PD; 7/17 mentioned positive FH of ET type tremor
among relatives: 6/17 tremor–mother (1 patient both
Table 1 The detailed demographic and clinical characteristics of every ET-PD patient
No. Symp. durat. FH Topography Later. Extr. tone SN+ Pharmacotherapy
1. 43 Yes H + A D Yes Yes DA, amantadine 200 mg, propranolol 80 mg
2. 6 Yes H + A D No No DA, clorazepate 10 mg
3. 21 No A + L B No Yes Propranolol 120 mg, clonazepam 2 mg
4. 3.5 Yes H + A S No Yes L-Dopa, pregabaline 75 mg
5. 10 No H + A D No Yes DA, bromazepam 1.5 mg, vit. E
6. 30 Yes H + A D No No L-Dopa
7. 6 No H + V + A D Yes Yes L-Dopa, DA, propranolol 80 mg, citalopram,
clonazepam 0.25 mg
8. 10 Yes A + L B Yes No L-Dopa, propranolol 80 mg
9. 11 No H + A + L B Yes Yes L-Dopa, DA, rasagiline 1 mg
10. 15 No A D No No Sertraline, zolpidem
11. 3 No A S No Yes Propranolol 40 mg
12. 45 Yes A S No Yes L-Dopa, DA
13. 3 Yes H + V + A D No Yes Clonazepam 2 mg, tiapride 150 mg
14. 1.5 Yes H + A S No Yes Paroxetine, clonazepam 0.25 mg, vit. E, coenzyme Q10
15. 10 No A B No No Gabapentine 100 mg, vinpocetine 20 mg, piracetam 400 mg, vit. E
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father), 1/17 tremor-grandmother. Thus, in the PD group
(n = 165): altogether 25/165 had positive FH: 9 had FH of
possible PD (5/9 mother, 1/9 brother, 1/9 sister, 1/9 grand-
mother, 1/9 aunt); and 16 positive FH of ET type tremor
(7/16 mother, 3/16 sister, 3/16 father, 1/16 aunt, 2/16- the
data missing to whom of relatives exactly ET type tremor
was positive).
Levodopa (n = 6, 40%), dopamine agonists (DA, n = 6,
40%), benzodiazepines (n = 6, 40%) and propranolol (n = 5,
33.3%) were prescribed separately or in combinations for
the patients with ET-PD.
When comparing the ET-PD patient group to other
groups of patients and controls (summarized in Table 2),
statistically significant differences were found: between
genders, there was a male (53.2%) predominance in
PD-only, and a female (66.4%) in ET-only group (χ2 test,
p = 0.007); within symptom duration, which was the lon-
gest (median 6 yrs) in the ET-PD group (Kruskal-Wallis
test, p = 0.003); between the rate of positive family history,
which was the most frequent (53.3%) in the ET-PD group
(χ2 test, p = 0.005); in cogwheel sign, which was the most
frequently detected (91.5%) in PD-only group (χ2 test,
p < 0.001); in pyramidal signs, which were the most fre-
quent (13%) both in ET-PD and PD-only groups (χ2 test,
p = 0.009); also there were differences in the mean H&Y
scores with the higher (2.6 ± 0.8) in ET-PD group (t test,
p = 0.021). When comparing TD to non-TD PD-only
groups, they did not differ in any clinical or demographic
aspects, except for H&Y scores, which were higher in
non-TD (1.96 ± 0.74 vs. 1.6 ± 0.70, t test, p = 0.009). As ex-
pected, the UPDRS part III points significantly differedbetween the PD-only vs. ET-only groups, with the highest
scores being in the PD-only group (p = 0.021). We did not
detect any significant differences in the results of the sub-
jective clinimetric scales HAD and SF-36 subcomponents)
between the patient groups, only to controls (Table 2).
A correlative analysis, taking into account all the
groups, revealed significant correlations between: an age
and HAD-Depression (r = 0.22, p = 0.034); the duration of
symptoms and HAD-Anxiety (r = 0.26, p = 0.009), H&Y
scale (r = 0.4, p < 0.001), UPDRS part I (Mentation, Behavior
and Mood) scores (r = -0.33, p = 0.043).
Ultrasonographic findings
The TCS findings in the patient groups and controls are
given in Table 3. When comparing TD to non-TD PD-
only patients, they differed in the mean largest SN
(SNMax) plots, which were higher for non-TD group
(0.35 ± 0.17 vs. 0.28 ± 0.25 cm2, t test, p = 0.015). Signifi-
cant differences were detected: between the frequency of
disrupted/absent nuclei raphe (χ2 test, p < 0.001), which
were the most affected in ET-PD (38.5%) and PD-only
(38.6%) groups; in hyperechogenic lentiform nucleus
(LN+) rate, which was the most frequently (26.7%) ob-
served in ET-PD group (χ2 test, p = 0.006); within red
nucleus hyperechogenicity rate (χ2 test, p = 0.005), the
most frequently visible in ET-only (17.2%) and the con-
trol (18.8%) groups (probably because the SN + did not
overtake its area). Specifically in the subgroup of ET-
PD patients, to whom ET-type tremor presented ≥5 yrs
before the onset of PD-related symptoms (n = 10), the
LN + was detected in only 2/10 (20%) of them (χ2 test,
p = 0.088).
Table 2 Demographic and clinical characteristics of ET-PD patients in comparison to ET-only, PD-only patients and controls
Demographic and
clinical characteristics
Patients (n = 272) P value* Controls (n = 101) P value#
ET-PD (n = 15) ET-only (n = 116) PD-only (n = 141)
Age, y 69 ± 9.6 63.9 ± 14.4 64.4 ± 11.2 NS 61.7 ± 12.4 NS
Gender (male) 6 (40) 39 (33.6) 75 (53.2) 0.007 56 (55.4) 0.004
Sympt. duration y 6 (3-15) 5 (1-10) 3 (1-6) 0.003a N/A N/A
Family history + 8 (53.3) 35 (31.3) 23 (17) 0.005 4 (4.3) <0.001
Toxic exposure 3 (20) 19 (16.4) 23 (16.3) NS 16 (15.8) NS
Living in rural 4 (26.7) 19 (16.4) 29 (20.6) NS 16 (15.8) NS
Cogwheel sign 4 (26.7) 3 (2.6) 129 (91.5) <0.001 0 (0) <0.001
Pyramidal signs 2 (13.3) 3 (2.6) 19 (13.5) 0.009 10 (9.9) 0.025
H&Y stage 2.6 ± 0.8 N/A 1.8 ± 0.8 0.012 N/A N/A
UPDRS part I 1 (0-1) 1 (0-3) 3 (1-4) NS N/A N/A
UPDRS part II 5 (4-6) 13 (12-13) 11 (7-16) NS N/A N/A
UPDRS part III 5 (3-6) 4 (1-6) 14 (9-20) 0.021b N/A N/A
HAD-Anxiety 1 (1-8) 6 (2-10) 8 (5-11) NS 5 (3-8) NS
HAD-Depression 4 (4-7) 4 (2-6) 6 (4-9) NS 3 (1-7) NS
SF36-PF 53.3 ± 17.6 52.3 ± 31.8 45.9 ± 25.3 NS 70 ± 24.2 0.001c
SF36-RLPF 16.7 ± 28.9 33.1 ± 29 33.3 ± 27 NS 50.2 ± 29.4 0.020d
SF36-RLEF 33.3 ± 57.7 51.4 ± 30 40.8 ± 34.2 NS 59 ± 32.2 NSe
SF36-EF 43.3 ± 10.4 43.8 ± 24.8 44.5 ± 19.4 NS 58.8 ± 17.1 0.007f
SF36-EW 66.7 ± 38.9 52.5 ± 26 53.7 ± 19.3 NS 64.7 ± 15.8 NSg
SF36-SF 58.3 ± 19.1 57.3 ± 31.5 53.8 ± 24.9 NS 75.7 ± 46.7 0.050h
SF36-P 66.7 ± 18.8 65.7 ± 26.7 49.5 ± 30.7 NS 61.7 ± 28.2 NS
SF36-GH 28.3 ± 2.9 35 ± 19.4 31.1 ± 16.9 NS 49.1 ± 18.5 <0.001i
Values are presented as mean ± SD or median with IQR, and numbers (percentages). *- p values were counted comparing 3 groups of patients, #- p values were
counted comparing 4 groups of subjects where available.
The post hoc multiple comparisons between the groups by Tukey HSD and LSD tests revealed significant differences:
a-ET-PD vs. PD-only p = 0.001, 95% CI 2.8-13.1, ET-only vs. PD-only p = 0.002, 95% CI 1.12-5.87; b-LSD test only PD vs. ET-only p = 0.009, 95% CI 2.32-15.61; ET-PD vs.
ET-only p = 0.008, 95% CI 4.86-31.08; c-PD-only vs. control group p = 0.001, 95% CI 8.37-39.88; d-PD-only vs. control group p = 0.05, 95% CI 0.01-33.83; e-LSD test
only, PD-only vs. control group p = 0.018, 95% CI 3.16-33.19; f-PD-only vs. control group p = 0.011, 95% CI 2.48-26.16; ET-only vs. control group p = 0.024, 95% CI
1.46-28.67; g-LSD test only, PD-only vs. controls p = 0.021, 95% CI 1.66-20.19; ET-only vs. controls p = 0.026, 95% CI 1.46-22.76; h-PD-only vs. control group p = 0.039, 95% CI
0.77-43.1; i-PD-only vs. controls p < 0.001, 95% CI 7.24-28.62; ET-only vs. controls p = 0.018, 95% CI 1.77-26.34; LSD test only, PD-only vs. ET-only p = 0.031, 95% CI 1.52-30.94.
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from the ET-PD group. For 3/6 (50%) patients a clearly
reduced asymmetrical striatal radioligand binding was
detected, i.e. signs for the degenerative Parkinsonism, for
2/6 (33.3%) - without evidence of dopaminergic dysfunc-
tion on DaTscan, and for 1/6 (16.7%) the patient-DaTscan
result was debated, without a clear conclusion.
A correlative analysis, taking into account all the groups
together, revealed a significant relationship between:
the age and V3 diameter (r = 0.23, p < 0.001), the right
(r = 0.18, p = 0.004) and also the left LV diameters (r = 0.25,
p < 0.001); the SNMax plot and V3 diameter (r = 0.15,
p = 0.04).
Discussion
The main echo findings of the present study in the pa-
tients with overlapping ET-PD phenotype, were similar
to PD-only group, as more than two thirds (66.7%) ofET-PD patients had the SN+ at a threshold value ≥0.20 cm2,
and raphe nuclei interruptions or absence were detected
in 38.5%. From the ultrasonographic comparative point,
the closest comparison to our study was the recent inves-
tigation by Kim et al., focusing on TCS in 47 PD-only and
64 ET-only patients, in relation with putative pre-motor
symptoms of PD [23]. The authors detected a significant
association between SN+ and each pre-motor symptom
in the ET-only group, linking the results that SN + in
patients with ET is influenced by the putative pre-motor
symptoms of PD [23]. Combining the most prevalent
non-motor features for PD to TCS imaging, including ol-
factory, autonomic (gastrointestinal) dysfunction, depres-
sion with anxiety and REM sleep behavioural disorder,
would prove very useful [22,30].
The single distinguishing TCS feature, was an increased
frequency (26.7%) of detected LN + in the group of pa-
tients with ET-PD (Figure 1), however significant when
Table 3 Ultrasonographic (TCS) findings in the groups of patients and control subjects
TCS parameters Patients (n = 272) P value* Controls (n = 101) P value#
ET-PD (n = 15) ET-only (n = 116) PD-only (n = 141)
SNR cm
2 0.22 ± 0.12 0.20 ± 0.11 0.27 ± 0.14 <0.001a 0.15 ± 0.09 <0.001d
SNL cm
2 0.27 ± 0.15 0.23 ± 0.14 0.31 ± 0.16 0.001b 0.16 ± 0.09 <0.001e
SNMax cm
2 0.30 ± 0.16 0.24 ± 0.14 0.34 ± 0.16 <0.001c 0.18 ± 0.09 <0.001f
SNMax ≥0.20 cm
2 10 (66.7) 49 (42.2) 106 (75.2) <0.001 18 (17.8) <0.001
SNMax ≥0.26 cm
2 8 (53.3) 38 (32.8) 89 (63.1) 11 (10.9)
V3 cm 0.69 ± 0.31 0.58 ± 0.28 0.58 ± 0.27 NS 0.53 ± 0.25 NSg
LVR cm 1.81 ± 0.3 1.82 ± 0.26 1.78 ± 0.24 NS 1.79 ± 0.26 NS
LVL cm 1.78 ± 0.26 1.81 ± 0.3 1.75 ± 0.24 NS 1.74 ± 0.26 NS
Raphe – or +/- 5 (38.5) 22 (20) 51 (38.6) 0.007 11 (13.1) <0.001
Caudate + 0 (0) 2 (1.7) 2 (1.4) NS 0 (0) NS
Lentiform + 4 (26.7) 20 (17.2) 12 (8.5) NS 4 (4) 0.006
Thalamus + 2 (13.3) 10 (8.6) 10 (7.1) NS 10 (9.9) NS
Red nucleus + 1 (6.7) 20 (17.2) 9 (6.4) 0.008 19 (18.8) 0.005
Values are presented as mean ± SD or numbers (percentages). *-p values were counted comparing 3 groups, #-p values were counted comparing 4 groups.
The post hoc multiple comparisons by Tukey HSD and LSD tests showed statistically significant differences between the latter groups:
a-ET-only vs. PD-only p < 0.001, 95% CI 0.03-0.11; b-ET-only vs. PD-only p < 0.001, 95% CI 0.03-0.12; c-ET-only vs. PD-only p < 0.001, 95% CI 0.04-0.13; d-ET-only vs.
PD-only p < 0.001, 95% CI 0.03-0.11; ET-only vs. controls p = 0.032, 95% CI 0.003-0.09; PD-only vs. controls p < 0.001, 95% CI 0.07-0.16; e-ET-only vs. PD-only p < 0.001,
95% CI 0.03-0.12; ET-only vs. controls p = 0.03, 95% CI 0.02-0.12; PD-only vs. controls p < 0.001, 95% CI 0.1-0.2; f-ET-only vs. PD-only p < 0.001, 95% CI 0.04-0.13; ET-only
vs. controls p = 0.003, 95% CI 0.02-0.12; PD-only vs. controls p < 0.001, 95% CI 0.1-0.2; by LSD only ET-PD vs. controls p = 0.019, 95% CI 0.02-0.17; g-LSD test only ET-PD
vs. controls p = 0.042, 95% CI 0.005-0.303.
Figure 1 Images of a patient with ET-PD-RLS, suggesting an alternative diagnosis of parkinsonism after paraclinical tests.
A-cranial MRI, T2W, B-cranial CT, markedly hyperintensive signals bilaterally in the lentiform nucleus (white arrows), C-TCS, mesencephalic
plane, moderate SN and red nucleus hyperechogenicity (white arrow), D-TCS, diencephalic plane, bilaterally markedly hyperechogenic
lentiform nuclei (white arrows).
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such ultrasonographic findings are characteristic to PS
[20,21]. In the study of Behnke et al., unilateral or bi-
lateral LN + was found in 13/18 (72.2%) patients with
PSP, in 23/32 (71.9%) patients with parkinsonian variant
of multisystem atrophy (MSA-P), and in only 10 of 88
(11.4%) patients with idiopathic PD [31]. Taking into ac-
count the SN echogenicity and V3 diameter, the normal
SN indicated MSA-P rather than PD, whereas V3 dilata-
tion of >1.0 cm in combination with LN+ indicated PSP
rather than PD [32]. In the present study, when analyzing
the subgroup of ET-PD patients, to whom ET-type tremor
presented ≥5 yrs before the onset of PD-related symp-
toms, TCS helped to reveal the LN+ in only 2/10 (20%) of
them, this was indistinguishable even from the control
group (p = 0.088). This is probably because a few patients,
with a short disease duration (<5 yrs), who looked like
they may be developing co-morbid PD clinically, may have
had alternative diagnosis for PS (and were misclassified as
having ET-PD). See an illustrative case (Figure 1) with
clinical ET-PD plus restless legs syndrome (ET-PD-RLS),
where different imaging methods were applied and the
findings were described, suggesting an alternative diagno-
sis–idiopathic basal ganglia calcification (IBGC). Chrono-
logically, first of all, cranial MRI was performed to this
patient at another hospital, which was evaluated as
normal, the patient was subsequently diagnosed as having
ET-PD plus RLS at HLUHS and was then referred for
TCS examination, followed by cranial CT scan, which
confirmed TCS findings. These echo findings in ET-PD
group have similarities to the results of the recent post-
mortem study, where in 12.4% (11/89) of the ET patients
atypical PS pathological findings were detected (ET-PSP)
[19]. Also the frequency of pyramidal signs in our study,
which were the most often detected (13%) both in ET-PD
and PD-only groups (p = 0.009), might also indicate an
alternative diagnosis in some cases (excluding those, to
whom pyramidal signs can be explained by the central
spinal stenosis with myelopathy, acute or residual cere-
brovascular events and post-traumatic residual signs).
The significant differences between the patient groups
were detected when comparing clinical results. In the
ET-PD group male to female rate was closer to PD-only
(40% and 53.2% respectively). There were similarities in
the duration of symptoms between the ET-PD and ET-only
groups (median 6 yrs and 5 yrs respectively). Chaudhuri
et al. showed that longstanding isolated asymmetrical pos-
tural tremor may evolve to PD, and this was supported in
5 of the 13 reported cases (38%) by abnormal radionuclide
imaging [33]. Whereas in 5 out of 24 cases, uncertain par-
kinsonian signs and normal imaging led to a change of the
diagnosis to ET [33]. DaTscan imaging was performed to
6 (40%) patients from the ET-PD group, and for the ma-
jority (3/6, 50%) of patients a clearly reduced asymmetricalstriatal radioligand binding was detected, i.e. signs for the
degenerative Parkinsonism, thus for 2/6 (33.3%) - without
clear evidence of dopaminergic dysfunction on DaTscan.
Ceravolo et al emphasized that the clinical presentation of
isolated tremors (of unilateral postural, unilateral mixed
or unilateral rest) is insufficient to allow a precise early-
stage diagnosis, as PD tremor could be very different
ranging from typical rest to unilateral postural or mixed
tremor, whereas detection of presynaptic dopaminergic
dysfunction by SPECT could lead to diagnosis of atypical
tremor disorders at very early stage [34].
According to the UPDRS part III points, the significant
differences were detected between PD-only vs. ET-only
groups as expected, with the highest scores, in PD-only
group (p = 0.021). There were no significant differences
between ET-PD vs. PD-only groups, with just a tendency
of the less severe Parkinsonism in ET-PD patients than
that of PD patients (median 5 vs. 14 points). The similar
findings were detected in a retrospective study by Simões
and colleagues [17].
A positive family history rate was highest in the ET-PD
group. This feature was similar to ET-only group (53.3%
and 31.3% respectively). Even though ET is one of the
most common genetic disorders, it is yet to be identified
as being a specific gene mutation. Puschmann et al. exten-
sively investigated large kindred whose family members
had PD, ET, RLS and depression, an overlap (mainly ET-PD
or PD-RLS) was detected in 64% (7/11) of these individuals
[35]. The fact that the risk of ET is significantly increased
in relatives of patients with PD, suggests the possibility that
both conditions are genetically related and probably share
common hereditary predisposition [6]. In the recent study
of Barut et al., the patients with ET–PD displayed a higher
frequency of familial tremor history, as was recorded in our
study [16]. The same authors also found significantly lower
scores compared to the ET-only group on several cognitive
tests, and lower levodopa responsiveness [9,16].
Our sample of the ET-PD patients, which accounted
for only 5.5% of all patients, was small (rare phenotype)
and quite heterogeneous itself. The small number of cases
with this phenotype was also reported in other studies:
n = 9 [16], and n = 18 out of 387 cases with Parkinson
and 110 with tremor [17]. This causes speculation to
support the hypothesis that the linkage between the two
separate disorders could be rather coincidental [8]. How-
ever, to clearly support or deny the hypothesis about the
higher risk for the patients with ET-only to develop PD,
another study design (a larger cohort, follow-up) is
necessary.
For most of the ET-PD patients the anti-parkinsonian
medications that were prescribed (60%), less than a half
(40%) responded well to levodopa, and the majority
(66.7%) required additional medications traditionally used
for ET.
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positive cogwheel rigidity in 26.7% of the ET-PD patients
vs. 91.5% in the PD-only group, but a much higher mean
of H&Y scores (2.6 ± 0.8 vs.1.8 ± 0.8 respectively). More-
over, in the majority of the ET-PD group, 11/15 (73.3%)
of patients had asymmetrical distribution of tremor, and
8/15 (53.3%) had an onset of tremor after 50 yrs. The
results of the radionuclide imaging study by Coria et al.
suggested that the current diagnostic criteria for ET
should be revised to include asymmetry and late-onset
tremor as predictors of nigrostriatal denervation [10].
This is because often found isolated action tremor is a
frequent presenting symptom in a subset of individuals
with PD, who are often misdiagnosed as having ET
[10,34].
The main limitations of our study were that there was
no pathological or functional imaging confirmation for
all ET-PD patients. Also there was a limited time for a
follow-up.
Conclusions
The main TCS findings of the present study in patients
with overlapping ET-PD phenotype were similar to
PD-only group, taking into account the rate of the SN +
and of the red nucleus, the raphe nuclei disruptions or ab-
sence. The clinical features linking ET-PD to PD-only
group were an asymmetrical and late-onset tremor for the
majority of ET-PD patients, and the presence of a rest
tremor on examination. Some ET patients, who look like
they may be developing co-morbid PD clinically, may have
alternative diagnosis for Parkinsonism, which can be
delineated by TCS examination. The highest positive
family history rate among ET-PD patients, compared to
ET-only and PD-only groups, indicates strong hereditary
predisposition and needs genetic underpinnings. An
addition of longitudinal follow-up studies is substantially
needed to increase diagnostic certainty, also the confirma-
tory neuropathological studies of ET-PD clinical pheno-
type are required to describe and quantify the pathological
changes.
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